Impact of anti-PLK1 siRNA-containing F3-targeted liposomes on the viability of ...

• Autor(es): Gomes-da-Silva, Lígia C. ; Ramalho, José S. ; de Lima, M. C. P. ; Simões, Sérgio ; Moreira, João N.
• Data: 2013
• Identificador Persistente: http://hdl.handle.net/10316/25573
• Origem: Estudo Geral - Universidade de Coimbra
• Assunto(s): Nanotechnology; siRNA; PLK1; Gene silencing; Paclitaxel; Prostate cancer
• Tipo de Documento: Artigo
• Idioma: Inglês

Descrição

We have previously described the development of novel sterically stabilized F3-targeted pH-sensitive liposomes, which exhibited the ability to target both cancer and endothelial cells. Herein, the therapeutic potential of those liposomes was assessed upon encapsulation of a siRNA against a well-validated molecular target, PLK1. Treatment of prostate cancer (PC3) and angiogenic endothelial (HMEC-1) cells with F3-targeted liposomes containing anti-PLK1 siRNA resulted in a significant decrease in cell viability, which was mediated by a marked PLK1 silencing, both at the mRNA and protein levels. Furthermore, pre-treatment of PC3 cells with F3-targeted liposomes containing anti-PLK1 siRNA enabled a 3-fold reduction of paclitaxel IC50 and a 2.5-fold augment of the percentage of cancer cells in G2/mitosis arrest, which ultimately culminated in cell death. Overall, the F3-targeted nanocarrier containing an anti-PLK1 siRNA might constitute a valuable system for prostate cancer treatment, either applied in a single schedule or combined with conventional chemotherapy. The work was supported by the Portugal–Spain capacitation program in Nanoscience and Nanotechnology (ref.: NANO/NMed-AT/0042/2007) and by Grant PEst-C/SAU/LA0001/2011.